activity
20232025
most citedDesign Considerations for a Phase II platform trial in Major Depressive Disorder

3 citations · 7 across the 9 of their papers we have counts for

collaborators

9 papers

stat.ME2025

Selection Bias in Hybrid Randomized Controlled Trials using External Controls: A Simulation Study

Han Chang Chiam, Franz König, Martin Posch

Hybrid randomized controlled trials (hybrid RCTs) integrate external control data, such as historical or concurrent data, with data from randomized trials. While numerous frequenti…

stat.ME2025

Covariate adjustment for linear models in estimating treatment effects in randomised clinical trials. Some useful theory to guide simulation

Stephen Senn, Franz König, Martin Posch

Building on key papers that were published in special issues of Biometrics in 1957 and 1982 we propose and develop a three-aspect system for evaluating the effect of fitting covari…

stat.ME2025

Graph Based, Adaptive, Multi Arm, Multiple Endpoint, Two Stage Design

Cyrus Mehta, Ajoy Mukhopadhyay, Martin Posch

The graph based approach to multiple testing is an intuitive method that enables a study team to represent clearly, through a directed graph, its priorities for hierarchical testin…

stat.ME2024

Stratification in Randomised Clinical Trials for Rare Diseases and Analysis of Covariance: Some Simple Theory and Recommendations

Stephen Senn, Franz König, Martin Posch

A simple device for balancing for a continuous covariate in clinical trials is to stratify by whether the covariate is above or below some target value, typically the predicted med…

stat.ME2024★ 1 cited

A two-step approach for analyzing time to event data under non-proportional hazards

Jonas Brugger, Tim Friede, Florian Klinglmüller +3

The log-rank test and the Cox proportional hazards model are commonly used to compare time-to-event data in clinical trials, as they are most powerful under proportional hazards. B…

stat.ME2023★ 1 cited

Efficiency of Multivariate Tests in Trials in Progressive Supranuclear Palsy

Elham Yousefi, Mohamed Gewily, Franz König +6

Measuring disease progression in clinical trials for testing novel treatments for multifaceted diseases as Progressive Supranuclear Palsy (PSP), remains challenging. In this study…

stat.ME2023★ 2 cited

A neutral comparison of statistical methods for time-to-event analyses under non-proportional hazards

Florian Klinglmüller, Tobias Fellinger, Franz König +10

While well-established methods for time-to-event data are available when the proportional hazards assumption holds, there is no consensus on the best inferential approach under non…

stat.AP2023★ 3 cited

Design Considerations for a Phase II platform trial in Major Depressive Disorder

Michaela Maria Freitag, Dario Zocholl, Elias Laurin Meyer +5

Major Depressive Disorder (MDD) is one of the most common causes of disability worldwide. Unfortunately, about one-third of patients do not benefit sufficiently from available trea…

stat.ME2023

Simultaneous inference procedures for the comparison of multiple characteristics of two survival functions

Robin Ristl, Heiko Götte, Armin Schüler +2

Survival time is the primary endpoint of many randomized controlled trials, and a treatment effect is typically quantified by the hazard ratio under the assumption of proportional…